Loading patent…
AssigneesThe Trustees of Columbia University in the City of New York, St. Luke's-Roosevelt Hospital Center
InventorsGerard M Turino, Shuren Ma, Yong Y Lin, Seymour Leiberman
Estimating the term…
The present invention relates to methods of diagnosing, monitoring, and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry employing an internal standard, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.
A method of validating whether a candidate compound is effective to treat, prevent, or ameliorate the effects of chronic obstructive pulmonary disease (COPD) comprising determining if the candidate compound decreases the degradation of elastin in a patient administered the candidate compound by measuring comprising an acylated pyridinoline, the amount of desmosine and isodesmosine in a sample of a body fluid or tissue of the patient, wherein a decrease in the presence of desmosine or isodesmosine compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.
A method of validating whether a candidate compound is effective to treat, prevent, or ameliorate the effects of chronic obstructive pulmonary disease (COPD) comprising determining if the candidate compound decreases the degradation of elastin in a patient administered the candidate compound by measuring comprising an acylated pyridinoline, the amount of desmosine and isodesmosine in a sample from the patient selected from the group consisting of plasma, urine, and sputum, using mass spectrometry employing an internal standard which comprises acylated pyridinoline wherein a decrease in the presence of desmosine and isodesmosine compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.
Dependencies are inferred from the claim text.